Description

Cardiogen, a bioregulatory peptide, promotes cardiac regeneration by stimulating cardiac progenitor cells, reduces apoptosis in heart cells, and aids in cancer therapy by inducing tumor cell apoptosis. (PMID: 20210190, PMID: 20396706)​

Cardiogen Research Topics:

1. Cardiac Regeneration

   Cardiogen stimulates the proliferation and differentiation of cardiac progenitor cells, leading to the regeneration of cardiac muscle cells. This aids in restoring cardiac function by regenerating damaged or diseased myocardium and reducing scar formation, which is beneficial for patients with heart failure and myocardial infarction. (PMID: 20210190)​ 

2. Anti-Apoptotic Effects in Cardiac Cells

   Cardiogen can inhibit apoptosis in cardiac cells by down-regulating the expression of the p53 protein. This helps in protecting heart cells from programmed cell death, which is crucial for maintaining healthy cardiac function. (PMID: 20210190)​

3. Cancer Research

   In cancer studies, particularly involving prostate cancer and sarcoma, Cardiogen has shown potential in modulating tumor growth by promoting apoptosis in tumor cells. This dual action—protecting cardiac cells while promoting tumor cell death—makes it a valuable candidate for cancer research. (PMID: 20396706)​

Structure

Molecular Formula: C1 8H31 N109
Molecular Weight: 489.5 g/mol 
PubChem CID: 11583989 
Alternative Names: SCHEMBL3194515

Source: PubChem 

Cardiogen and the Heart

In the heart, Cardiogen appears to stimulate cardiomyocyte proliferation while reducing fibroblast growth and development. This leads to decreased scar formation and improved long-term outcomes in regards to cardiac remodeling leading to heart failure. Additionally, it appears that Cardiogen can decrease p53 protein expression and thereby diminish rates of apoptosis [1]. 

Cardiogen and Cancer 

Even though Cardiogen reduces apoptosis in heart cells by down-regulating p53 expression, it may have the opposite effect in tumor cells. Research in rat models of M-1 sarcoma shows that apoptosis levels are higher in the tumor cells following Cardiogen administration. What is more, the effect is dose-dependent, indicating that the biological effect is real [2]. The peptide appears to enhance apoptosis in tumor cells and may be somewhat selective for tumor cells due to their enhanced and unusual vascular supply. This may make Cardiogen a targeted treatment for at least some types of cancer. In addition, if the peptide enhances the action of standard cancer treatments (as it does in heart disease treatment), then it may prove a very potent addition to the arsenal of cancer fighters. 

Doctors Levdik and Knyazkin, both of whom have worked in some capacity with Vladimir Khavinson through the St. Petersburg Institute of Bioregulation and Gerontology and the Russian Academy of Medical Sciences, have extensive experience researching the impact of amino acids and short peptides on both cancer and healthy tissues as they become dysfunctional and precancerous. Their work with Cardiogen has positioned it as the next possible candidate for approval, in Russia, for the treatment of sarcoma. 

Cardiogen and the Prostate 

Research in tissue cultures shows that Cardiogen, along with several similar peptides, alters the expression of signaling factors in fibroblasts of the prostate. Levels of these signaling factors are important in establishing favorable a microenvironment within tumors and may contribute to both the development and progression of prostate cancer. Solid evidence shows that the synthesis of these markers is substantially altered in aging and senescent fibroblasts, which may explain why prostate cancer is almost ubiquitous in older men but nearly unheard of in younger men [3]. In fact, studies show that Cardiogen can normalize levels of these signaling molecules to match or even improve upon what is seen in young cell cultures, suggesting that Cardiogen may be effective both in preventing prostate cancer and in controlling its progression once it develops [4]. 

Cardiogen Summary 

Cardiogen, while less researched than some other bioregulators, appears to have potent effects on multiple body tissues including the heart and prostate. Additionally, the peptide may be beneficial in the treatment of certain types of cancer, particularly sarcoma. Currently, the biggest benefits of Cardiogen appear to be in the settings of heart attack, hypertension, and chronic heart failure where the peptide not only offers benefits of its own accord but acts synergistically with established treatments. 

Cardiogen exhibits minimal side effects, good oral, and excellent subcutaneous bioavailability in mice. Per kg, dosage in mice does not scale to humans. Cardiogen for sale at Life Link Research is limited to educational and scientific research only, not for human consumption. Only buy Cardiogen if you are a licensed researcher. 

Article Author

The above literature was researched, edited, and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate from Case Western Reserve University School of Medicine and a B.S. in molecular biology. 

Scientific Journal Author 

Vladimir Khavinson is a Professor, resident of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice ­president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental, and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying the role of peptides in the regulation of the mechanisms of ageing. His main field of action is the design, pre-clinical, and clinical studies of new peptide geroprotectors. A 40-year­ investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of aging and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological Aspects of Genome Peptide Regulation” (Karger AG, 2005). Vladimir Khavinson introduced the scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversight over 200 Ph.D. and Doctorate theses from many different countries. 

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Cardiogen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Life Link Research and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

Referenced Citations 

1. N. I. Chalisova et al., “[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats],” Adv. Gerontol. Us12..ekhi Gerontol., vol. 22, no. 3, Qp. 409-413, 2009.
2. N. V. Levdik and I. V. Knyazkin, “Tumor ­modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats,” Bull. Exp. Biol. Med., vol. 148, no. 3, Qp. 433-436, SeR.:, 2009, doi: 10.1007/s10517-010-0730-9.
3. L. Begley, C. Monteleon, R. B. Shah, J. W. Macdonald, and J. A. Macoska, “CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro,” Aging Cell, vol. 4, no. 6, pp. 291-298, Dec. 2005, doi: 10.1111/j.1474-9726.2005.00173.x.
4. 0. V. KheTfets, V. 0. Poliakova, and I. M. Kvetnoi, “[Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging],” Adv. Gerontol. Uspekhi Gerontol., vol. 23, no. 1, RR- 68-70, 2010.